ES2013357A6 - Procedimiento de fabricacion de nuevos esteres de aminoacidos y de sus sales de adicion de acidos farmacologicamente aceptables. - Google Patents

Procedimiento de fabricacion de nuevos esteres de aminoacidos y de sus sales de adicion de acidos farmacologicamente aceptables.

Info

Publication number
ES2013357A6
ES2013357A6 ES8803342A ES8803342A ES2013357A6 ES 2013357 A6 ES2013357 A6 ES 2013357A6 ES 8803342 A ES8803342 A ES 8803342A ES 8803342 A ES8803342 A ES 8803342A ES 2013357 A6 ES2013357 A6 ES 2013357A6
Authority
ES
Spain
Prior art keywords
esters
enantiomers
diastereomers
new
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8803342A
Other languages
English (en)
Inventor
Klaus Dr Klessing
Chatterjee Shyman Dr Sunder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Willmar Schwabe GmbH and Co KG
Original Assignee
Dr Willmar Schwabe GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Willmar Schwabe GmbH and Co KG filed Critical Dr Willmar Schwabe GmbH and Co KG
Publication of ES2013357A6 publication Critical patent/ES2013357A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROCEDIMIENTO DE FABRICACION DE NUEVOS ESTERES DE AMINOACIDOS Y DE SUS SALES DE ADICION DE ACIDOS FARMACOLOGICAMENTE ACEPTABLES. LA INVENCION SE REFIERE A UN PROCEDIMIENTO DE PREPARACION DE NUEVOS ESTERES DE AMINOACIDOS DE FORMULA GENERAL (I), CARACTERIZADO PORQUE SE HACE REACCIONAR UNA TREO-4-ALCOXI-5-HIDROXIMETIL-2(5H)-FURANONA CON UN DERIVADO DEL ACIL-AMINOACIDO CONVENIENTEMENTE PROTEGIDO, OBTENIENDOSE, SEGUN LA QUIRALIDAD DE LOS REACTIVOS, DISTINTOS FORMAS ISOMERICAS, QUE SON SEPARADAS POR DISTINTOS PROCEDIMIENTOS. LOS COMPUESTOS ASI OBTENIDOS TIENEN APLICACION FARMACOLOGICA COMO ANTICOLVULSIVOS Y ANTIEPILEPTICOS FACILMENTE ABSORBIBLES.
ES8803342A 1987-11-04 1988-11-02 Procedimiento de fabricacion de nuevos esteres de aminoacidos y de sus sales de adicion de acidos farmacologicamente aceptables. Expired - Lifetime ES2013357A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873737399 DE3737399A1 (de) 1987-11-04 1987-11-04 Aminosaeureester, verfahren zu ihrer herstellung und ihre verwendung

Publications (1)

Publication Number Publication Date
ES2013357A6 true ES2013357A6 (es) 1990-05-01

Family

ID=6339748

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8803342A Expired - Lifetime ES2013357A6 (es) 1987-11-04 1988-11-02 Procedimiento de fabricacion de nuevos esteres de aminoacidos y de sus sales de adicion de acidos farmacologicamente aceptables.

Country Status (11)

Country Link
US (1) US4965283A (es)
EP (1) EP0349609B1 (es)
JP (1) JPH0753724B2 (es)
KR (1) KR970002469B1 (es)
AT (1) ATE79116T1 (es)
AU (1) AU610294B2 (es)
CA (1) CA1338572C (es)
DE (2) DE3737399A1 (es)
ES (1) ES2013357A6 (es)
WO (1) WO1989004310A1 (es)
ZA (1) ZA888160B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
WO2002073208A2 (en) * 2001-03-13 2002-09-19 Queen's University At Kingston Anti-epileptogenic agents
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) * 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2002096424A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents
WO2003099272A1 (en) 2002-05-22 2003-12-04 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
JP2006508986A (ja) 2002-11-20 2006-03-16 エルラント ゲネ セラペウチクス エルエルシー ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法
CN119113197A (zh) * 2024-09-12 2024-12-13 安徽万欣通医疗科技有限公司 一种甲基丙烯酸3,4-二氯-5-羟基-5h-呋喃-2-酮酯改性的抗菌骨水泥

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH450395A (de) * 1965-07-26 1968-01-31 Hommel Ag Verfahren zur Herstellung eines Lactons
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe

Also Published As

Publication number Publication date
EP0349609A1 (de) 1990-01-10
DE3737399A1 (de) 1989-05-18
AU2619288A (en) 1989-06-01
KR970002469B1 (en) 1997-03-05
ZA888160B (en) 1989-07-26
KR890701574A (ko) 1989-12-21
DE3873529D1 (de) 1992-09-10
AU610294B2 (en) 1991-05-16
EP0349609B1 (de) 1992-08-05
ATE79116T1 (de) 1992-08-15
JPH0753724B2 (ja) 1995-06-07
JPH02502012A (ja) 1990-07-05
WO1989004310A1 (fr) 1989-05-18
US4965283A (en) 1990-10-23
CA1338572C (en) 1996-09-03

Similar Documents

Publication Publication Date Title
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
SI0725779T1 (es)
AU623555B2 (en) Disinfecting compositions and methods therefor
EP0386757A3 (en) Biodegradable poly (phosphate esters)
UA27749C2 (uk) Заміщені циклопропіламіно-1,3,5-триазини, їх оптичні ізомери, рацемічні суміші чи їх солі приєднання нетоксичних фармацевтично прийнятних кислот, що мають фармакологічну активність, спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
AP9100310A0 (en) Tnf inhibitors
MX9304787A (es) Prodrogas de acidos de imidazolcarboxilicos y composiciones farmaceuticasque las contienen.
ATA86885A (de) Verfahren zur herstellung lagerstabiler, schnellzerfallender pharmazeutischer wirkstoff-presslinge
UA19782A (uk) Спосіб одержаhhя біциклічhих складhих ефірів або їх фармацевтичhо прийhятhих солей
KR970002469B1 (en) Aminoacid ester process for their manufacture and their use
CA2071907A1 (en) Bcrf1 proteins as inhibitors of interferon-y
HU9603489D0 (en) Medical composition and process for producing it
IL142803A0 (en) Pharmaceutical compositions containing r-tofisopam
EP0576915A3 (en) Cyclopentanperhydrophenanthren-17beta-(3-furyl)-3-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders
AU6808190A (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
ZA973156B (en) Process for the production of enantiomerically-pure azetidine-2-carboxylic acid.
PL319752A1 (en) Silylation process
HUT49869A (en) Process for producing 5-chloro-3-chlorosulfonyl-2-thiophenecarboxylic acid esters
HUT59307A (en) Process for producing pharmaceutical compositions comprising zofenopril and suitable for treating arthritis
ATE209040T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen, die durch endothelzellen und fibrinogen ausgelöst werden
GR3024707T3 (en) Digitoxigenin and dihydrodigitoxigenin 3beta-derivatives and pharmaceutical compositions comprising same for the treatment of cardiovascular disorders
EP0410379A3 (en) Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins
JPS6450852A (en) Manufacture of l,l or d,d or racemic n6- benzyloxycarbonyl-2,6-diaminopimelamic acid
RO100033A2 (ro) Procedeu de obtinere a s(-)3-(3-tertbutilamino-2-hidroxipropoxi)-4-(n-morfolino)-1,2,5-tiadiazolului
AU1195497A (en) Use of alpha,alpha-diphenylacetic acid-4-(n-methyl-piperidyl)ester as anti-spasmodic

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2008-11-02